Menu

Primary Menu

Skip to content
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News
Show Header Sidebar Content
Twitter Email LinkedIn

Shift Pharmaceuticals

Shift’s News

  • FDA grants Orphan Drug status for Shift’s lead compound for SMA May 14, 2020

Follow Us

Twitter Email LinkedIn

Footer Menu

Skip to content
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News
Copyright © 2021 Shift Pharmaceuticals. All Rights Reserved.
Scroll Up
  • Home
  • About Shift
  • Shift’s Focus
  • Shift’s Technology
  • Shift News